rs2303729 — LTBP4

LTBP4 Val194Ile — TGF-β Sequestration and Duchenne Muscular Dystrophy Severity

Latent TGF-β-binding protein 4 (LTBP4) is a structural component of the extracellular matrix that performs two intertwined jobs: it scaffolds elastic fibers in connective tissue and captures latent TGF-β1¹¹ TGF-β1
transforming growth factor β1, a pleiotropic cytokine that drives fibrosis, immune modulation, and tissue remodeling when activated, holding it in an inert reservoir until controlled release. rs2303729 is one of four linked missense variants in the LTBP4 gene that together define two functionally distinct protein isoforms — IAAM and VTTT — with meaningfully different capacities to sequester TGF-β.

The IAAM isoform (carrying Ile at position 194, encoded by the A allele of rs2303729) binds latent TGF-β1 with higher avidity, keeping more TGF-β locked in the extracellular matrix and away from its receptor. The VTTT isoform (Val at 194, G allele) holds TGF-β less tightly, releasing more free cytokine. In healthy individuals this difference is largely inconsequential, but in any disease driven by pathological TGF-β/SMAD signaling — most prominently Duchenne muscular dystrophy (DMD), but also dystrophin-deficient cardiomyopathy and potentially fibrotic conditions — the distinction becomes clinically meaningful.

The Mechanism

rs2303729 encodes a Val→Ile substitution at position 194²² Val→Ile substitution at position 194
p.Val194Ile — both valine and isoleucine are nonpolar aliphatic amino acids, but the side-chain geometry difference affects protein folding in the LTBP4 matrix-binding domain within the matrix-binding domain of LTBP4. It forms a haplotype with three additional nonsynonymous variants — rs1131620 (T787A), rs1051303 (T820A), and rs10880 (T1140M) — that are in strong linkage disequilibrium and co-inherited as IAAM (protective) or VTTT (risk).

Flanigan et al. 2016³³ Flanigan et al. 2016
Genotype-Specific Interaction of Latent TGFβ Binding Protein 4 with TGFβ. PLoS One 11:e0150358 demonstrated the molecular basis in a protein binding assay: LTBP4 protein carrying the IAAM residues bound significantly more latent TGF-β1 than the VTTT protein under identical conditions. Cells expressing VTTT-LTBP4 released more free TGF-β, activating downstream SMAD2/3 phosphorylation at higher levels. In DMD, where muscle fibers are mechanically fragile and each contraction-injury cycle triggers inflammatory and fibrotic signaling, excess TGF-β drives progressive replacement of muscle with fibrous tissue — the histological substrate of functional decline.

The Evidence

The clinical evidence for LTBP4 as a DMD modifier is among the strongest for any genetic modifier in a Mendelian disease. The original discovery by Flanigan et al. Ann Neurol 2013⁴⁴ Flanigan et al. Ann Neurol 2013
LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy. Ann Neurol 73:177–187 showed that DMD patients homozygous for the IAAM haplotype lost the ability to walk at 12.5 ± 3.3 years (glucocorticoid-treated) versus 10.7 ± 2.1 years for those carrying one or two copies of the VTTT haplotype — a difference comparable in magnitude to the benefit of steroid therapy itself (p=6×10⁻⁴, HR=0.52 for IAAM homozygotes).

Independent validation across European cohorts came from van den Bergen et al. J Neurol Neurosurg Psychiatry 2015⁵⁵ van den Bergen et al. J Neurol Neurosurg Psychiatry 2015
Validation of genetic modifiers for Duchenne muscular dystrophy. JNNP 86:563–571, confirming that IAAM homozygosity is a robust predictor of later ambulatory loss across institutions and genotyping platforms.

Cardiac implications were characterised by Bello et al. J Neuromuscul Dis 2024⁶⁶ Bello et al. J Neuromuscul Dis 2024
The IAAM LTBP4 Haplotype is Protective Against Dystrophin-Deficient Cardiomyopathy, which found IAAM carriers had +2.90% higher ejection fraction (p=0.038) and −10.48 mL/m² lower end-diastolic volume (p=0.0098) in echocardiographic data from 819 DMD patients — indicating the TGF-β sequestration effect extends to the heart.

Beyond DMD, LTBP4 variants have been studied in fibrotic and pulmonary conditions, with the VTTT isoform's elevated TGF-β release implicated in greater fibrosis severity in several connective tissue contexts. The full disease spectrum and relevance to non-DMD individuals remains active research territory.

Practical Implications

For individuals who do not have DMD, rs2303729 genotype is a background modifier with no established clinical significance in the general population. The variant may become more relevant in the context of:

• Confirmed DMD: IAAM homozygosity is the most validated prognostic modifier, and knowing this genotype informs prognosis discussions and the expected benefit window for glucocorticoid therapy. Testing DMD patients for the full LTBP4 haplotype (all four SNPs) provides the most complete modifier assessment.
• Familial DMD carrier screening: Because LTBP4 haplotype modifies phenotype but not penetrance, it should be interpreted alongside dystrophin mutation type.
• Research context: Elevated baseline TGF-β signaling from VTTT homozygosity may compound fibrotic responses in other musculoskeletal or cardiac conditions, though this remains hypothesis-generating outside DMD.

Interactions

rs2303729 must be interpreted in the context of the full LTBP4 haplotype. The three co-segregating variants — rs1131620 (T787A), rs1051303 (T820A), and rs10880 (T1140M) — contribute jointly to TGF-β binding capacity, and the haplotype-level analysis (IAAM vs VTTT) has stronger effect sizes and replication than any single variant alone. In all published DMD modifier analyses, the composite IAAM or VTTT haplotype — not rs2303729 in isolation — is the biologically and clinically meaningful unit.